ZA201503979B - Treatment of diseases involving mucin - Google Patents
Treatment of diseases involving mucinInfo
- Publication number
- ZA201503979B ZA201503979B ZA2015/03979A ZA201503979A ZA201503979B ZA 201503979 B ZA201503979 B ZA 201503979B ZA 2015/03979 A ZA2015/03979 A ZA 2015/03979A ZA 201503979 A ZA201503979 A ZA 201503979A ZA 201503979 B ZA201503979 B ZA 201503979B
- Authority
- ZA
- South Africa
- Prior art keywords
- treatment
- diseases involving
- involving mucin
- mucin
- diseases
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/22—Cysteine endopeptidases (3.4.22)
- C12Y304/22032—Stem bromelain (3.4.22.32)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/22—Cysteine endopeptidases (3.4.22)
- C12Y304/22033—Fruit bromelain (3.4.22.33), i.e. juice bromelain
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Inorganic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2012905519A AU2012905519A0 (en) | 2012-12-17 | Treatment of diseases involving mucin | |
| PCT/AU2013/001474 WO2014094041A1 (en) | 2012-12-17 | 2013-12-17 | Treatment of diseases involving mucin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201503979B true ZA201503979B (en) | 2017-11-29 |
Family
ID=50977393
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2015/03979A ZA201503979B (en) | 2012-12-17 | 2015-06-03 | Treatment of diseases involving mucin |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11369666B2 (enExample) |
| EP (1) | EP2931296B1 (enExample) |
| JP (1) | JP6502853B2 (enExample) |
| KR (1) | KR102255753B1 (enExample) |
| CN (2) | CN104968358B (enExample) |
| AU (3) | AU2013362878B2 (enExample) |
| CA (1) | CA2895149C (enExample) |
| DK (1) | DK2931296T3 (enExample) |
| ES (1) | ES2727686T3 (enExample) |
| NZ (1) | NZ631536A (enExample) |
| TR (1) | TR201907858T4 (enExample) |
| WO (1) | WO2014094041A1 (enExample) |
| ZA (1) | ZA201503979B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018521069A (ja) | 2015-07-16 | 2018-08-02 | プロスペクト チャーターケア アールダブリュエムシー，エルエルシー ディ／ビー／エイ ロジャー ウィリアムズ メディカル センターＰｒｏｓｐｅｃｔ Ｃｈａｒｔｅｒｃａｒｅ Ｒｗｍｃ，Ｌｌｃ Ｄ／Ｂ／Ａ Ｒｏｇｅｒ Ｗｉｌｌｉａｍｓ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ | 腹膜癌を治療するための組成物及び方法 |
| EP3362085B1 (en) * | 2015-10-14 | 2023-06-07 | Newsouth Innovations Pty Limited | Compositions for the treatment of diseases involving mucin |
| JPWO2017195792A1 (ja) * | 2016-05-13 | 2019-03-14 | 国立大学法人 熊本大学 | 新規なｐｅｇ修飾酵素及びそれを用いた抗がん剤デリバリー |
| CN108066413A (zh) * | 2016-11-15 | 2018-05-25 | 李雁 | 标准桃金娘油的癌性黏液溶解作用及抗肿瘤新用途 |
| AU2019225453B2 (en) * | 2018-02-23 | 2025-03-13 | MUCPharm Pty Ltd | Formulations containing mucin-affecting proteases |
| ES2988904T3 (es) | 2019-03-07 | 2024-11-22 | Nobo Medicine Inc | Inhibidores de caspasa y métodos de utilización de los mismos |
| WO2021217221A1 (en) * | 2020-05-01 | 2021-11-04 | MUCPharm Pty Ltd | Preventing and treating viral infections |
| JP2024539275A (ja) * | 2021-10-27 | 2024-10-28 | エムユーシーファーム ピーティーワイ リミテッド | 呼吸器疾患を治療するための方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU212924B (en) | 1989-05-25 | 1996-12-30 | Chiron Corp | Adjuvant formulation comprising a submicron oil droplet emulsion |
| DE4302060A1 (de) * | 1993-01-26 | 1994-07-28 | Mucos Pharma Gmbh & Co | Verwendung von Bromelain zur Krebstherapie und/oder Metastasen-Prophylaxe |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| JPH08337532A (ja) * | 1995-06-14 | 1996-12-24 | Takeda Chem Ind Ltd | 医薬組成物 |
| AT408615B (de) | 1998-09-15 | 2002-01-25 | Immuno Ag | Neue influenzavirus-impfstoffzusammensetzung |
| GB9923176D0 (en) | 1999-09-30 | 1999-12-01 | Smithkline Beecham Biolog | Novel composition |
| CH695414A5 (de) * | 2001-05-30 | 2006-05-15 | Guenter Holzner | Kosmetische Präparate gegen die Alterung der menschlichen Haut in einer Mehrkammer-Mischpackung. |
| US6517832B1 (en) * | 2001-08-24 | 2003-02-11 | Jeffrey L. Marrongelle | Formulations and methods for treating chronic migraine |
| AU2004294986B2 (en) * | 2003-11-26 | 2010-09-09 | Hill's Pet Nutrition, Inc. | Method to reduce stool odor of companion animals |
| CA2522152A1 (en) * | 2004-10-07 | 2006-04-07 | Kabushiki Kaisha Sangi | Transdermal and transmucosal preparations |
| AR054822A1 (es) | 2005-07-07 | 2007-07-18 | Sanofi Pasteur | Emulsion inmuno adyuvante |
| US20080075710A1 (en) * | 2006-09-25 | 2008-03-27 | Liquid Potions Llc | Herbal composition for treating hangovers |
| US20100166726A1 (en) * | 2007-03-07 | 2010-07-01 | Northeastern University | Compositions for improving cellular uptake of a chemotherapeutic agent in a cell exhibiting mucin deregulation |
| TWI461193B (zh) * | 2009-07-24 | 2014-11-21 | Taipei Veterans General Hospital | 水飛薊或水飛薊賓用於治療神經受損之用途 |
| JP5614978B2 (ja) * | 2009-12-22 | 2014-10-29 | 独立行政法人農業・食品産業技術総合研究機構 | 穀物由来のプロアントシアニジン含有抽出物、及びその製造方法 |
| CN103285383B (zh) * | 2013-06-03 | 2015-01-07 | 海南通用同盟药业有限公司 | 一种包含菠萝蛋白酶的药物组合物及菠萝蛋白酶肠溶片 |
-
2013
- 2013-12-17 CA CA2895149A patent/CA2895149C/en active Active
- 2013-12-17 JP JP2015546778A patent/JP6502853B2/ja active Active
- 2013-12-17 TR TR2019/07858T patent/TR201907858T4/tr unknown
- 2013-12-17 ES ES13866447T patent/ES2727686T3/es active Active
- 2013-12-17 AU AU2013362878A patent/AU2013362878B2/en active Active
- 2013-12-17 WO PCT/AU2013/001474 patent/WO2014094041A1/en not_active Ceased
- 2013-12-17 NZ NZ631536A patent/NZ631536A/en unknown
- 2013-12-17 EP EP13866447.9A patent/EP2931296B1/en active Active
- 2013-12-17 CN CN201380070938.4A patent/CN104968358B/zh active Active
- 2013-12-17 KR KR1020157018076A patent/KR102255753B1/ko active Active
- 2013-12-17 DK DK13866447.9T patent/DK2931296T3/da active
- 2013-12-17 US US14/649,518 patent/US11369666B2/en active Active
- 2013-12-17 CN CN202211366234.9A patent/CN116077631A/zh active Pending
-
2015
- 2015-06-03 ZA ZA2015/03979A patent/ZA201503979B/en unknown
-
2017
- 2017-06-29 AU AU2017204436A patent/AU2017204436B2/en active Active
-
2019
- 2019-05-12 AU AU2019203315A patent/AU2019203315A1/en not_active Abandoned
-
2022
- 2022-06-27 US US17/850,593 patent/US20220401529A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN116077631A (zh) | 2023-05-09 |
| CN104968358B (zh) | 2022-11-18 |
| US20220401529A1 (en) | 2022-12-22 |
| AU2017204436B2 (en) | 2019-05-30 |
| KR20150096445A (ko) | 2015-08-24 |
| EP2931296A4 (en) | 2016-08-10 |
| JP6502853B2 (ja) | 2019-04-17 |
| EP2931296A1 (en) | 2015-10-21 |
| JP2016502981A (ja) | 2016-02-01 |
| AU2013362878A1 (en) | 2015-06-18 |
| NZ631536A (en) | 2016-12-23 |
| CA2895149C (en) | 2023-08-22 |
| AU2019203315A1 (en) | 2019-05-30 |
| CN104968358A (zh) | 2015-10-07 |
| TR201907858T4 (tr) | 2019-06-21 |
| ES2727686T3 (es) | 2019-10-17 |
| HK1211213A1 (en) | 2016-05-20 |
| AU2013362878B2 (en) | 2017-03-30 |
| WO2014094041A1 (en) | 2014-06-26 |
| EP2931296B1 (en) | 2019-02-27 |
| DK2931296T3 (da) | 2019-06-03 |
| KR102255753B1 (ko) | 2021-05-26 |
| US20150343035A1 (en) | 2015-12-03 |
| US11369666B2 (en) | 2022-06-28 |
| AU2017204436A1 (en) | 2017-07-20 |
| CA2895149A1 (en) | 2014-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL235593A0 (en) | Bone marrow suppression treatment | |
| IL232530A0 (en) | Combined cancer treatment | |
| IL261659A (en) | Brain cancer treatment | |
| GB201506561D0 (en) | Treatment of amblyopia | |
| IL228430A0 (en) | Cancer treatment | |
| ZA201503979B (en) | Treatment of diseases involving mucin | |
| EP2903644A4 (en) | TREATMENT OF CANCER | |
| EP2869833A4 (en) | TREATMENT OF INFLAMMATORY SKIN DISORDERS | |
| ZA201500547B (en) | Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases | |
| GB201217892D0 (en) | Treatment of cancer | |
| SI2892925T1 (sl) | Kombinacijsko zdravljenje raka | |
| ZA201501038B (en) | Treatment of wax | |
| GB201207907D0 (en) | Treatment of depression | |
| EP2911662A4 (en) | METHOD OF TREATING A DISEASE | |
| GB201217890D0 (en) | Treatment of cancer | |
| AU2012905519A0 (en) | Treatment of diseases involving mucin | |
| GB201204645D0 (en) | Treatment of disease | |
| GB201221118D0 (en) | Methods of treatment | |
| GB201216748D0 (en) | Methods of treatment | |
| GB201216740D0 (en) | Methods of treatment | |
| GB201206330D0 (en) | Methods of treatment | |
| GB201206325D0 (en) | Methods of treatment | |
| GB201206324D0 (en) | Methods of treatment | |
| GB201206326D0 (en) | Methods of treatment | |
| GB201218263D0 (en) | Treatment of autism |